Rs10192566

From SNPedia

Jump to: navigation, search
is asnp
is mentioned by
dbSNPrs10192566
hapmaprs10192566
hgdprs10192566
ensemblrs10192566
gopubmedrs10192566
scholarrs10192566
googlers10192566
pharmgkbrs10192566
hgvbaseg2prs10192566
medrefsnprs10192566
23andMers10192566
SNP Nexus

GeneLPIN1
Chromosome2
Orientationplus
Position11807878
GenotypeEffect
rs10192566(C;C)if diabetic, poorer response to rosiglitazone
rs10192566(C;G)if diabetic, better response to rosiglitazone
rs10192566(G;G)if diabetic, better response to rosiglitazone


Genotypes Magnitude Summary
Rs10192566(C;C) if diabetic, poorer response to rosiglitazone
Rs10192566(C;G) if diabetic, better response to rosiglitazone
Rs10192566(G;G) if diabetic, better response to rosiglitazone
A total of 262 Korean type-2 diabetes patients were treated with 12 weeks of rosiglitazone at 4mg/day and genotyped to reveal that rs10192566(G) allele carriers responded better than (C) carriers. Patients with rs10192566(G) alleles had a larger decrease in fasting plasma glucose, 2-h postprandial glucose, and HbA1c than rs10192566(C;C) homozygotes. None of the other LPIN1 gene SNPs tested were associated with response.[PMID 18693052]

Note: rs11693809, rs10192566, and rs2278513 are in nearly complete linkage disequilibrium (D'>0.958, r(2) >0.882).

PharmGKBPA162316734
Name
AnnotationA study in patients with type 2 diabetes treated with rosiglitazone showed that this SNP in the LPIN1 gene was significantly associated with rosiglitazone treatment response. rs11693809 and rs2278513 are in nearly complete linkage disequilibrium with rs10192566.
GeneLPIN1
Featue
EvidencePubMed ID:18693052
Drugsrosiglitazone
DiseasesDiabetes Mellitus, Type 2
Curation LevelCurated
Retrieved from "http://www.snpedia.com/index.php/Rs10192566"